The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.
Germline mutations in POLE and POLD1 are linked to variable cancer risks, with findings highlighting mutation-specific differences that refine tumor predisposition assessment.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A 15-year-old girl developed distinctive, painless, whip-like streaks across her trunk and back after receiving combination chemotherapy for ovarian yolk sac tumor. What’s your diagnosis?